Abstract:Abstract Huntington’s disease is caused by a CAG / polyglutamine repeat expansion. Mutated CAG repeats undergo somatic instability, resulting in tracts of several hundred CAGs in the brain; and genetic modifiers of Huntington’s disease have indicated that somatic instability is a major driver of age of onset and disease progression. As the CAG repeat expands, the likelihood that exon 1 does not splice to exon 2 increases, resulting in two transcripts that encode full-length huntingtin protein, as well as the highly pathogenic and aggregation-prone exon 1 huntingtin protein. Strategies that target the huntingtin gene or transcripts are a major focus of therapeutic development. It is essential that the levels of all isoforms of huntingtin protein can be tracked, to better understand the molecular pathogenesis, and to assess the impact of huntingtin protein-lowering approaches in preclinical studies and clinical trials. Huntingtin protein bioassays for soluble and aggregated forms of huntingtin protein are in widespread use on the homogeneous time-resolved fluorescence and Meso Scale Discovery platforms, but these do not distinguish between exon 1 huntingtin protein and full-length huntingtin protein. In addition, they are frequently used to quantify huntingtin protein levels in the context of highly expanded polyglutamine tracts, for which appropriate protein standards do not currently exist. Here, we set out to develop novel huntingtin protein bioassays to ensure that all soluble huntingtin protein isoforms could be distinguished. We utilized the zQ175 Huntington’s disease mouse model that has ∼190 CAGs, a CAG repeat size for which protein standards are not available. Initially, 30 combinations of six antibodies were tested on three technology platforms: homogeneous time-resolved fluorescence, amplified luminescent proximity homogeneous assay and Meso Scale Discovery, and a triage strategy was employed to select the best assays. We found that, without a polyglutamine-length-matched standard, the vast majority of soluble mutant huntingtin protein assays cannot be used for quantitative purposes, as the highly expanded polyglutamine tract decreased assay performance. The combination of our novel assays, with those already in existence, provides a tool-kit to track: total soluble mutant huntingtin protein, soluble exon 1 huntingtin protein, soluble mutant huntingtin protein (excluding the exon 1 huntingtin protein) and total soluble full-length huntingtin protein (mutant and wild type). Several novel aggregation assays were also developed that track with disease progression. These selected assays can be used to compare the levels of huntingtin protein isoforms in a wide variety of mouse models of Huntington’s disease and to determine how these change in response to genetic or therapeutic manipulations.

Native Mutant Huntingtin in Human Brain

HAP40 is a conserved central regulator of Huntingtin and a specific modulator of mutant Huntingtin toxicity

Soluble N-terminal Fragment of Mutant Huntingtin Protein Impairs Mitochondrial Axonal Transport in Cultured Hippocampal Neurons.

Mutant Huntingtin and Glycogen Synthase Kinase 3‐β Accumulate in Neuronal Lipid Rafts of a Presymptomatic Knock‐in Mouse Model of Huntington's Disease

Essential sequence of the N-terminal cytoplasmic localization-related domain of huntingtin and its effect on huntingtin aggregates

Identification of Full-Length Wild-Type and Mutant Huntingtin Interacting Proteins by Crosslinking Immunoprecipitation in Mice Brain Cortex

A Novel Human Embryonic Stem Cell‐derived Huntington's Disease Neuronal Model Exhibits Mutant Huntingtin (mhtt) Aggregates and Soluble Mhtt‐dependent Neurodegeneration

Developmental and physiological impacts of pathogenic human huntingtin protein in the nervous system

Expression of mutant exon 1 huntingtin fragments in human neural stem cells and neurons causes inclusion formation and mitochondrial dysfunction

Mutant HTT protein decreases with CAG repeat expansion: implications for therapeutics and bioassays.

Global Proteome and Ubiquitinome Changes in the Soluble and Insoluble Fractions of Q175 Huntington Mice Brains

Demonstration of prion-like properties of mutant huntingtin fibrils in both in vitro and in vivo paradigms

Synaptic Mutant Huntingtin Inhibits Synapsin-1 Phosphorylation And Causes Neurological Symptoms

Peripheral sequestration of huntingtin delays neuronal death and depends on N-terminal ubiquitination

Region-specific pro-survival signaling and global neuronal protection by wild-type Huntingtin

Development of novel bioassays to detect soluble and aggregated Huntingtin proteins on three technology platforms

Endogenous Huntingtin aggregates are a huge organized scaffold and mold for Golgi apparatus impaired by mutant Huntingtin protein

Suppression of the Argininosuccinase Acid Lyase Gene by Mutant Huntingtin with Polyglutamine Expansion

Free-Energy Landscape of the Amino-Terminal Fragment of Huntingtin in Aqueous Solution

Rapid and high-purity differentiation of human medium spiny neurons reveals LMNB1 hypofunction and subtype necessity in modeling Huntington’s disease

Unraveling the Molecular Complexity of N-Terminus Huntingtin Oligomers: Insights into Polymorphic Structures